# ATHE earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ATHE) · [Earnings tab](https://www.lopjlb.com/stock/ATHE?tab=earnings)

Updated: 2026-08-28T06:21:04

Quarters analyzed: 1

## Cross-quarter narrative

As of the 2021 Q2 call, Alterity Therapeutics reported solid Phase I safety data for ATH434, launched the bioMUSE natural history study, secured a new composition-of-matter patent, and advanced PBT2 into an antimicrobial resistance (AMR) license. The company held $35 million in cash, with operating losses in line with expectations. Preparations for a Phase II ATH434 trial in multiple system atrophy (MSA) were underway, but the start depended on pending FDA and European health authority feedback, introducing regulatory uncertainty. A partial clinical hold on PBT2 for Alzheimer's added timeline risk for the AMR program. Demand visibility remained limited, relying on bioMUSE data to shape Phase II enrollment. Key fears included regulatory uncertainty due to lack of MSA trial precedent, clinical development risk for Phase II efficacy, funding risk despite current cash, competition in alpha-synuclein targeting, and unclear market size for PBT2 in AMR. Milestones such as Phase I completion, patent grant, and Michael J. Fox Foundation grant were delivered, while bioMUSE, PBT2 AMR license, and Phase II preparation remained on track.

## Latest CallCard · Q2

Alterity reports solid Phase I safety, a new bioMUSE natural history study and patent, while preparing a Phase II ATH434 trial for MSA and expanding PBT2 into antimicrobial resistance, backed by a $35M cash position.

**Guidance:** maintained — Management reiterated that Phase II preparation is on schedule and expects to start the trial in the second half of the year.

**Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.2

Prepared remarks highlight progress, new data, patents and funding, using upbeat language such as "very pleased" and "exciting"

### Demand visibility

Limited visibility; relies on bioMUSE data to shape Phase II enrollment

The bioMUSE natural history study in early MSA patients is intended to inform patient selection and efficacy endpoints for the upcoming Phase II trial, per FDA encouragement.

### Margins / costs

Operating loss and cash burn in line with expectations

Operating loss of $8.6M and net cash outflow of $7.3M matched budget; cash balance stands at $35M after a fully subscribed $35M capital raise.

### Capital allocation

Capital raised is allocated to ATH434 development and discovery work

Proceeds from the $35M placement are being used for the bioMUSE study, Phase II trial preparation, ongoing discovery programs and general working capital.

### Milestones

- **ATH434 Phase I trial** [delivered]: Phase I showed safety, tolerability and no cardiac liability at clinically tested doses
- **bioMUSE natural history study** [on_track]: Study launched to generate data that will inform Phase II design for MSA
- **New composition of matter patent** [delivered]: US Patent Office allowed a patent covering >150 novel compounds related to iron redistribution
- **PBT2 license for AMR** [on_track]: Exclusive worldwide rights from UniQuest to develop zinc ionophore therapy against antimicrobial‑resistant infections
- **Michael J. Fox Foundation grant** [delivered]: ~$500k grant to evaluate ATH434 in a primate Parkinson's disease model
- **ATH434 Phase II trial preparation** [on_track]: Manufacturing, preclinical work and site selection progressing; trial expected to start H2
- **European regulatory feedback** [at_risk]: Awaiting guidance from European health authorities, which could affect trial timelines
- **PBT2 partial clinical hold** [at_risk]: Hold from FDA for Alzheimer’s program may impact future AMR development; team planning mitigation

### Fears / risks

- **Regulatory uncertainty**: Pending FDA and European feedback on Phase II design and lack of precedent for MSA trials
- **Clinical development risk**: Phase II may not meet efficacy endpoints despite preparatory work
- **Funding risk**: Future cash needs depend on additional capital raises despite current $35M balance
- **Competition**: Other companies are pursuing alpha‑synuclein targeting therapies
- **Market risk for PBT2**: Unclear clinical path and market size for antimicrobial‑resistance indication
- **Partial clinical hold**: FDA hold on PBT2 for Alzheimer’s could delay or alter AMR development plans
- **Execution risk**: Manufacturing scale‑up and site selection complexities for Phase II
- **Intellectual property risk**: Reliance on newly issued patent portfolio for next‑generation compounds

## Quarter one-liners

- **2021 Q2:** Alterity reports solid Phase I safety, a new bioMUSE natural history study and patent, while preparing a Phase II ATH434 trial for MSA and expanding PBT2 into antimicrobial resistance, backed by a $35M cash position.

## Theme arcs

- **ATH434 clinical development** (new): Phase I delivered; Phase II preparation on track pending regulatory feedback
- **PBT2 antimicrobial resistance program** (new): License on track but partial clinical hold for Alzheimer's creates uncertainty
- **Regulatory engagement** (new): Awaiting FDA and European guidance on Phase II design may delay trial initiation
- **Natural history study (bioMUSE)** (new): Study on track to inform Phase II enrollment
- **Intellectual property** (new): New composition of matter patent delivered
- **Funding position** (new): $35M cash balance; future needs depend on additional capital raises
- **Competitive landscape** (new): Other companies pursuing alpha-synuclein targeting therapies
- **Market risk for PBT2 AMR** (new): Unclear clinical path and market size for antimicrobial resistance indication

## Fear persistence

- **Regulatory uncertainty** [new]: Pending FDA and European feedback on Phase II design; lack of precedent for MSA trials
- **Clinical development risk** [new]: Phase II may not meet efficacy endpoints despite preparatory work
- **Funding risk** [new]: Future cash needs depend on additional capital raises despite current $35M balance
- **Competition** [new]: Other companies pursuing alpha-synuclein targeting therapies
- **Market risk for PBT2 AMR** [new]: Unclear clinical path and market size for antimicrobial resistance indication

## Guidance path

2021 Q2:maintained

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ATHE`